JP Morgan Chase
NAMS icon

JP Morgan Chase’s NewAmsterdam Pharma NAMS Stock Holding History

JP Morgan Chase’s Portfolio NAMS Stock Details NAMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$25.9M Sell
884,228
-115,748
-12% -$3.77M ﹤0.01% 1867
2025
Q4 		$35.1M Sell
999,976
-302,522
-23% -$11M ﹤0.01% 1605
2025
Q3 		$37M Sell
1,302,498
-156,399
-11% -$3.75M ﹤0.01% 1616
2025
Q2 		$26.4M Buy
1,458,897
+467,579
+47% +$8.53M ﹤0.01% 1751
2025
Q1 		$20.3M Buy
991,318
+930,341
+1,526% +$20.7M ﹤0.01% 1919
2024
Q4 		$1.57M Buy
60,977
+38,626
+173% +$820K ﹤0.01% 4326
2024
Q3 		$371K Buy
22,351
+14,280
+177% +$247K ﹤0.01% 5096
2024
Q2 		$155K Buy
8,071
+3,752
+87% +$75.3K ﹤0.01% 5282
2024
Q1 		$102K Buy
+4,319
New +$87.7K ﹤0.01% 5667
2023
Q4 		– Sell
-2,622
Closed -$24.3K – 7748
2023
Q3 		$24.3K Sell
2,622
-8,841
-77% -$95.7K ﹤0.01% 6021
2023
Q2 		$136K Sell
11,463
-10,904
-49% -$145K ﹤0.01% 5306
2023
Q1 		$301K Buy
22,367
+21,265
+1,930% +$268K ﹤0.01% 4807
2022
Q4 		$12K Buy
+1,102
New +$11K ﹤0.01% 5998

Other funds holding NAMS

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
DFO
Duquesne Family Office New York $3.38B AUM 61.92% 1-Year Est. Return

JP Morgan Chase's NAMS Position: Q1 2026 in Review

JP Morgan Chase reduced its NewAmsterdam Pharma (NAMS) stake by 12% in Q1 2026, selling an estimated $3.77M and leaving 884,228 shares worth $25.9M. The position accounts for ﹤0.01% of the portfolio, ranked #1867.

JP Morgan Chase first reported a position in NAMS in Q4 2022 and has held it in 13 quarters since. The position peaked at $37M in Q3 2025. 170 funds tracked by Wall St. Rank hold NAMS as of Q1 2026.

  • JP Morgan Chase held 884,228 shares of NewAmsterdam Pharma worth $25.9M as of Q1 2026.
  • JP Morgan Chase sold 115,748 NewAmsterdam Pharma shares in Q1 2026, an estimated $3.77M.
  • NewAmsterdam Pharma made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #1867 holding.
  • JP Morgan Chase first reported a position in NewAmsterdam Pharma in Q4 2022 and has held it in 13 quarters since.
  • JP Morgan Chase's NewAmsterdam Pharma position peaked at $37M in Q3 2025.
  • 170 funds tracked by Wall St. Rank held NewAmsterdam Pharma as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.